Stocklytics Platform
Asset logo for symbol INCY
Incyte
INCY76
$65.80arrow_drop_up0.93%$0.61
S&P500
Asset logo for symbol INCY
INCY76

$65.80

arrow_drop_up0.93%
Key Stats
Open$65.08
Prev. Close$65.19
EPS3.30
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range64.54
66.12
52 Week Range50.27
67.36
Ratios
EPS3.30
Fundamentals
Payout Ratio-
Industry average yield2.92%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

INCYarrow_drop_up1.72%
US Healthcare Sectorarrow_drop_up0.03%
US Marketarrow_drop_up0.83%
check_circle
INCY / Market
INCY exceeded the US Market which returned 0.83% over the last twenty four hours.
check_circle
INCY / Healthcare Sector
INCY exceeded the US Healthcare sector which returned 0.03% over the last twenty four hours.

Incyte (INCY) Statistics

Incyte Corp (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics. The company is known for its innovative approach to drug discovery, utilizing advanced technologies and collaboration with academic institutions and other industry partners to identify promising targets and develop potential therapies. With a market capitalization of over $20 billion, Incyte Corp is a leading player in the biotech sector.

When it comes to valuation metrics, Incyte Corp is often compared to its peers in the biotech industry. The company's price-to-earnings (P/E) ratio is a commonly used measure of valuation, and as of the latest financials, Incyte Corp has a P/E ratio of 22. This indicates that the market values the company's earnings at 22 times its current share price. Additionally, Incyte Corp has a forward P/E ratio of 17, suggesting that investors anticipate future growth in earnings.

add Incyte to watchlist

Keep an eye on Incyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Incyte (INCY) stock's performance compared to its sector and the market over the past year?

Over the past year, Incyte (INCY) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.68%, Incyte has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 50.98%, it has fallen short of the market average. This comparison highlights Incyte's performance relative to both its sector and the overall market over the last year.

help
What is the PE ratio of Incyte (INCY) stock?

The PE (Price to Earnings) ratio of Incyte (INCY) is currently 19.94. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

help
What is the EPS of Incyte (INCY) stock?

The Earnings Per Share (EPS) for Incyte (INCY), calculated on a diluted basis, is $3.3. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

help
What is the operating margin of Incyte (INCY) stock?

The operating margin for Incyte (INCY) is 10.47%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

help
What is the EBITDA of Incyte (INCY) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Incyte (INCY) is $979.82M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

help
How much debt does Incyte (INCY) have?

Incyte (INCY) has a total debt of $37.4M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$3.31B.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level